Alkermes (ALKS)
(Delayed Data from NSDQ)
$27.32 USD
-0.31 (-1.12%)
Updated Jul 31, 2024 04:00 PM ET
After-Market: $27.30 -0.02 (-0.07%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$27.32 USD
-0.31 (-1.12%)
Updated Jul 31, 2024 04:00 PM ET
After-Market: $27.30 -0.02 (-0.07%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Zacks News
BioMarin (BMRN) Q2 Earnings & Sales Top, Voxzogo Drives Sales
by Zacks Equity Research
BioMarin (BMRN) beats on earnings and sales estimates in the second quarter on the back of robust demand for Voxzogo.
Bristol-Myers (BMY) Q2 Earnings, Sales Miss, '23 View Lowered
by Zacks Equity Research
Bristol-Myers' (BMY) second-quarter 2023 earnings and sales miss estimates due to generic erosion for the oncology drug Revlimid. The company also cuts its forecast for 2023.
Alkermes (ALKS) Q2 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Alkermes (ALKS) reports encouraging second-quarter results, wherein both earnings and revenues beat estimates. This is due to strong growth in commercial execution of its proprietary products, Lybalvi and Vivitrol.
GSK Beats on Q2 Earnings & Sales, Raises 2023 Guidance
by Zacks Equity Research
GSK's revenues benefit from strong growth across all segments, especially HIV and vaccine. GSK raises guidance for earnings and sales. Shares rise in pre-market trading post the announcement.
Compared to Estimates, Alkermes (ALKS) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Alkermes (ALKS) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Alkermes (ALKS) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Alkermes (ALKS) delivered earnings and revenue surprises of 14.58% and 7.83%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Biogen (BIIB) Beats on Q2 Earnings & Sales, Announces Job Cuts
by Zacks Equity Research
Biogen (BIIB) beats second-quarter estimates for earnings and sales. It maintains 2023 guidance. Stock up in pre-market.
Philips (PHG) Q2 Earnings Beat Estimates, Revenue Rise Y/Y
by Zacks Equity Research
Philips' (PHG) second-quarter results benefit from robust performances by the Diagnosis & Treatment and the Connected Care businesses.
Gilead (GILD) Ends Myelodysplastic Syndromes Study on Magrolimab
by Zacks Equity Research
Gilead Sciences, Inc. (GILD) discontinues phase III ENHANCE study, evaluating the potential of magrolimab as a treatment for higher-risk myelodysplastic syndromes, due to futility based on a planned analysis.
Vir Biotechnology (VIR) Down on Influenza Study Failure
by Zacks Equity Research
Vir Biotechnology (VIR) crashes after the phase II study evaluating VIR-2482 for preventing symptomatic influenza A illness fails to meet goals.
Alkermes (ALKS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Higher sales of Alkermes' (ALKS) key drugs like Vivitrol, Aristada and Lybalvi are likely to have driven second-quarter sales.
J&J (JNJ) Q2 Earnings & Sales Top, '23 View Upped, Stock Jumps
by Zacks Equity Research
J&J (JNJ) beats estimates for second-quarter earnings and sales. It raises full-year sales and earnings guidance.
Will Alnylam Pharmaceuticals (ALNY) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Recursion (RXRX) Stock Surges 191% in 3 Months: Here's Why
by Zacks Equity Research
Recursion's (RXRX) shares rallied almost 191% over the past three months, owing to artificial intelligence-driven acquisitions and strategic collaborations to advance drug development.
Apellis (APLS) Plunges on Safety Issues With Eye Treatment
by Zacks Equity Research
Apellis (APLS) suffers a setback on reports of six events of retinal vasculitis (or inflammation) following treatment with Syfovre (pegcetacoplan injection).
Alkermes (ALKS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pieris (PIRS) Pursues Strategic Alternatives, Stock Rises
by Zacks Equity Research
Pieris (PIRS) announces strategic update after partner AstraZeneca terminated collaboration agreement and returned the rights to elarekibep.
Novartis (NVS) Q2 Earnings & Revenues Top, Guidance Raised
by Zacks Equity Research
Novartis (NVS) beats on earnings and sales in the second quarter and raises its annual guidance on strong momentum.
BridgeBio (BBIO) Up as Heart Drug Meets Primary Goal in Study
by Zacks Equity Research
BridgeBio's (BBIO) shares surge on announcing positive data from a late-stage study evaluating acoramidis for patients with transthyretin amyloid cardiomyopathy.
Corcept's (CORT) Early-Stage Study on NASH Reveals Positive Data
by Zacks Equity Research
Corcept's (CORT) early-stage candidate miricorilant, evaluated to treat patients with presumed non-alcoholic steatohepatitis, shows encouraging data.
Frequency (FREQ) Up 77% on Merger Deal With Korro Bio
by Zacks Equity Research
Post-merger, Frequency (FREQ) focuses on advancing RNA editing programs. This combined entity is set to operate under the name Korro Bio, which will apply to trade on the NASDAQ under the ticker symbol KRRO.
Gilead's (GILD) Veklury Gets FDA Nod for Label Expansion
by Zacks Equity Research
Gilead's (GILD) antiviral treatment Veklury (remdesivir) has now been approved for the treatment of COVID-19 patients with severe renal impairment, including those on dialysis.
Eli Lilly (LLY) to Buy Versanis, Strengthen Obesity Portfolio
by Zacks Equity Research
For the purchase of Versanis, Lilly (LLY) agrees to pay up to $1.93 billion in cash.
Perrigo (PRGO) Gets FDA Nod for First OTC Birth Control Pill
by Zacks Equity Research
Following the FDA approval, Perrigo's (PRGO) Opill is the first ever over-the-counter birth control pill. The drug will be made available in the United States early next year.
First Wave (FWBI) Down 32% on Cystic Fibrosis Study Setback
by Zacks Equity Research
Initial data from First Wave's (FWBI) mid-stage study evaluating its investigational oral capsule in cystic fibrosis patients did not likely meet its primary endpoint.